{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:01:36Z","timestamp":1774335696528,"version":"3.50.1"},"reference-count":19,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>Immunoglobulin A vasculitis (IgAV) is a systemic small-vessel vasculitis. Although corticosteroids (CS) are the primary treatment for gastrointestinal manifestations associated with IgAV, some patients develop refractory or recurrent symptoms such as vomiting and abdominal pain despite CS treatment. Dapsone, a synthetic sulfone antimicrobial, has been used to treat cutaneous purpura in IgAV, but few authors have reported its use for refractory gastrointestinal symptoms. In this retrospective observational study, we describe results in 7 children with IgAV who were treated with dapsone for abdominal pain resistant to CS. Dapsone rapidly relieved abdominal pain in all 7 patients, who then were tapered off CS without relapse. Side effects of mild methemoglobinemia and hemolysis appeared to be manageable with planned monitoring and dose adjustment; a single patient who discontinued dapsone had fatigue and hypoxia associated with methemoglobinemia. No side effects were life-threatening. Dapsone may be considered as a therapeutic option for gastrointestinal symptoms refractory to CS in children with IgAV.<\/jats:p>","DOI":"10.1542\/peds.2021-055884","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T08:12:07Z","timestamp":1660723927000},"source":"Crossref","is-referenced-by-count":9,"title":["Dapsone for Refractory Gastrointestinal Symptoms in Children With Immunoglobulin A Vasculitis"],"prefix":"10.1542","volume":"150","author":[{"given":"Masashi","family":"Yoshida","sequence":"first","affiliation":[{"name":"aDivision of Gastroenterology and Hepatology, Saitama Children\u2019s Medical Center, Saitama, Japan"},{"name":"*These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Nambu","sequence":"additional","affiliation":[{"name":"aDivision of Gastroenterology and Hepatology, Saitama Children\u2019s Medical Center, Saitama, Japan"},{"name":"*These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"bDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"bDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Hara","sequence":"additional","affiliation":[{"name":"aDivision of Gastroenterology and Hepatology, Saitama Children\u2019s Medical Center, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Iwama","sequence":"additional","affiliation":[{"name":"aDivision of Gastroenterology and Hepatology, Saitama Children\u2019s Medical Center, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Mizuochi","sequence":"additional","affiliation":[{"name":"bDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan"},{"name":"*These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"9","key":"2023110816290797800_B1","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9566","key":"2023110816290797800_B2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0140-6736(07)60474-7","article-title":"Clinical update: Henoch-Sch\u00f6nlein purpura","volume":"369","author":"Saulsbury","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"2023110816290797800_B3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2006.03.024","article-title":"Early prednisone therapy in Henoch-Sch\u00f6nlein purpura: a randomized, double-blind, placebo-controlled trial","volume":"149","author":"Ronkainen","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"2023110816290797800_B4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1542\/peds.2009-3348","article-title":"Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Sch\u00f6nlein purpura","volume":"126","author":"Weiss","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"2023110816290797800_B5","doi-asserted-by":"crossref","first-page":"e0170259","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"2023110816290797800_B6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1651-2227.2001.tb01370.x","article-title":"Intravenous immunoglobulin therapy for severe digestive manifestations of Henoch-Sch\u00f6nlein purpura","volume":"90","author":"Lamireau","year":"2001","journal-title":"Acta Paediatr"},{"issue":"1","key":"2023110816290797800_B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12969-018-0285-2","article-title":"Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature","volume":"16","author":"Crayne","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"2023110816290797800_B8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2023110816290797800_B9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3345\/kjp.2019.00514","article-title":"Treatment of refractory IgA vasculitis with dapsone: a systematic review","volume":"63","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"},{"issue":"5","key":"2023110816290797800_B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023110816290797800_B11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mehy.2017.07.018","article-title":"Dapsone as a potential treatment option for Henoch-Sch\u00f6nlein Purpura (HSP)","volume":"108","author":"Lee","year":"2017","journal-title":"Med Hypotheses"},{"issue":"2","key":"2023110816290797800_B12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1523-1747.ep12555654","article-title":"Dapsone suppresses integrin-mediated neutrophil adherence function","volume":"98","author":"Booth","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2023110816290797800_B13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/014107688307600717","article-title":"Dapsone in allergic vasculitis: its use in Henoch-Sch\u00f6nlein disease following vaccination","volume":"76","author":"Ledermann","year":"1983","journal-title":"J R Soc Med"},{"issue":"2","key":"2023110816290797800_B14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5507\/bp.2017.044","article-title":"Dapsone treatment is efficient against persistent cutaneous and gastrointestinal symptoms in children with Henoch-Sch\u00f6nlein purpura","volume":"162","author":"Volejnikova","year":"2018","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"11","key":"2023110816290797800_B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/adc.2009.182394","article-title":"Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children","volume":"95","author":"Jauhola","year":"2010","journal-title":"Arch Dis Child"},{"issue":"2","key":"2023110816290797800_B16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"15","key":"2023110816290797800_B17","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/cncr.25904","article-title":"Dapsone-induced methemoglobinemia: a dose-related occurrence?","volume":"117","author":"Esbenshade","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"2023110816290797800_B18","first-page":"171","article-title":"Effect of dapsone on haemoglobin concentration in patients with leprosy","volume":"62","author":"Byrd","year":"1991","journal-title":"Lepr Rev"},{"issue":"3","key":"2023110816290797800_B19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.det.2010.03.014","article-title":"Innovative use of dapsone","volume":"28","author":"Wozel","year":"2010","journal-title":"Dermatol Clin"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055884\/1561315\/peds_2021055884.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055884\/1561315\/peds_2021055884.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:31:33Z","timestamp":1699461093000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/3\/e2021055884\/188779\/Dapsone-for-Refractory-Gastrointestinal-Symptoms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,17]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-055884","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"e2021055884"}}